Navigation Links
Algeta Appoints Andrew Kay as President and Chief Executive Officer
Date:12/11/2008

OSLO, December 11 /PRNewswire-FirstCall/ --

- Appointment Enhances Algeta's Commercial Capabilities and Aims to Accelerate Further Development of Alpharadin in Advanced Prostate Cancer

Algeta ASA (OSE: ALGETA), the Norwegian cancer therapeutics company, announces that Mr. Andrew Kay has been appointed as President and Chief Executive Officer and will take up the role on 19 January 2009. Dr. Thomas Ramdahl will continue as Executive Vice President and Chief Technology Officer (CTO).

Mr. Kay (53), B. Pharm., will join Algeta from Renovo plc (LSE: RNVO) where he was Executive Director, Commercial. He brings more than 25 years of commercial experience in the pharmaceutical sector, where he has managed the successful licensing and launch of several new chemical entities. At Renovo, he played a crucial role in securing the company's major licensing agreement in 2007 with Shire plc to develop and commercialise Juvista, Renovo's lead drug for the prevention and reduction of scarring following surgery.

At Algeta, Mr. Kay will be responsible for enhancing the Company's commercial capabilities and initially will be seeking commercial development partners for Algeta's lead product candidate, Alpharadin, which entered an international phase III clinical trial in 2008 as a novel treatment for patients with skeletal metastases from hormone refractory prostate cancer. He will be based in the UK.

Prior to joining Renovo in 2003, Mr. Kay was Global Head of Marketing and Sales and a Member of the Healthcare Committee and Pharmaceutical Executive Committee at Novartis in Basel, Switzerland, where he had worldwide responsibility for the sales and marketing of Novartis' pharmaceutical portfolio. Before that he held several other senior commercial positions in Europe and the USA with AstraZeneca, Eli Lilly, Sandoz and Boots covering leading therapeutic areas, including oncology. He has successfu
'/>"/>

SOURCE Algeta ASA
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
2. Codexis Appoints Singapore Laboratories Managing Director
3. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
4. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
5. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
6. NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection
7. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
8. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
9. NeurogesX Appoints New Director to the Board
10. Alba Therapeutics Appoints Dr. Betsy Van Parijs as Its Senior Vice President, Clinical Development and Medical Affairs
11. Premier Research Appoints Melissa Jones as Vice President, International Business Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... RedBrick Health , a fast-growing leader in consumer ... EmblemHealth , the New York ... the RedBrick Compass health assessment, combined with the RedBrick ... members. EmblemHealth is among the first health plans in ...
(Date:1/15/2014)... January 15, 2014 The Microcompetition with Foreign ... disease. One of these latent viruses is the Epstein Barr ... (RA). Rheumatoid arthritis (RA) is a chronic inflammatory disease that ... study found that RA patients have high concentrations of EBV ...
(Date:1/15/2014)... TaiGen Biotechnology Company, Limited ("TaiGen") today announced that they ... Russian pharmaceutical company, to develop and commercialize nemonoxacin (Taigexyn ... , Turkey and other members ... antibiotic for the treatment of bacterial infections including those ...
(Date:1/14/2014)... As pet owners drew up their lists of New Year,s ... better care of my furry companion." Nowadays there are pet salons, ... cases to take the little canine or feline darlings along wherever ... buy some pricey toys at the pet store. But anyone who ...
Breaking Biology Technology:EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2
... SEATTLE, April 22 Trubion Pharmaceuticals, Inc. (Nasdaq: ... preclinical data regarding its SCORPION(TM) multispecific therapeutic technology ... Association of Cancer Research (AACR) in Denver. The ... of the bispecific CD79BxDR SCORPION molecule, its differentiation ...
... tasting rooms really help generate sales for wineries? According ... almost half of winery tasting room visitors purchase the ... "This research proves that the tasting room experience does ... sales," said Dr. Isabelle Lesschaeve, research director, consumer insights ...
... Microtest Laboratories ( www.microtestlabs.com ... to expand its position as a proven, one-stop provider ... services for manufacturers of medical devices or pharmaceuticals.Microtest ... ensure regulatory compliance as well as to achieve greater ...
Cached Biology Technology:Trubion Presents Preclinical Data on Its SCORPION(TM) Multispecific Therapeutics at the 2009 American Association of Cancer Research Annual Meeting 2Trubion Presents Preclinical Data on Its SCORPION(TM) Multispecific Therapeutics at the 2009 American Association of Cancer Research Annual Meeting 3Trubion Presents Preclinical Data on Its SCORPION(TM) Multispecific Therapeutics at the 2009 American Association of Cancer Research Annual Meeting 4Setting the Benchmark for Winery Tasting Room Research: An Emerging Region Gets a Global Perspective 2Microtest Labs Expands Clean Room, Contamination Testing Services 2Microtest Labs Expands Clean Room, Contamination Testing Services 3Microtest Labs Expands Clean Room, Contamination Testing Services 4
(Date:4/17/2014)... bone marrow need to produce hydrogen sulfide in order ... a new study from the Center for Craniofacial Molecular ... USC. , Professor Songtao Shi, principal investigator on the ... the cells governs the flow of calcium ions. The ... results in osteogenesis, or the creation of new bone ...
(Date:4/17/2014)... in Europe, Asia and the United States are spreading ... impacting native honeybee populations at this time, according to ... including Nosema microsporidia and Varroa ... to these invasive pests, which suggests to us that ... and the United States currently are not necessary in ...
(Date:4/17/2014)... IPCC meeting painted a stark warning on the possible ... a greenhouse effect 32 times that of carbon dioxide. ... humic substances act as fully regenerable electron acceptors which ... in wetlands instead of being released to the atmosphere. ... disrupted it may enter into a vicious cycle to ...
Breaking Biology News(10 mins):East African honeybees are safe from invasive pests… for now 2East African honeybees are safe from invasive pests… for now 3Methane climate change risk suggested by proof of redox cycling of humic substances 2
... Iceland, August 9, 2007 In a paper published ... (Nasdaq:DCGN) and academic colleagues from the National University Hospital ... discovery of two common single letter variations (SNPs) in ... account for virtually all cases of a major subtype ...
... anti-cancer therapy by blocking the molecular motors involved in ... by young Dutch researcher Dr. Nynke Dekker in one ... the European Science Foundation (ESF) and the European Heads ... are trying to stop tumor development by interfering with ...
... Today, researchers report for the first time ... are inherited only from the motherare directly linked to ... which highlights the role of mitochondrial genome variation in ... Genome Research ( www.genome.org ). According ...
Cached Biology News:deCODE discovers cause of major subtype of glaucoma 2ESF EURYI award winner aims to stop cancer cells reading their own DNA 2Scientists show that mitochondrial DNA variants are linked to risk factors for type 2 diabetes 2
... Immunogen KLH-conjugated, synthetic ... 47-66 (PAEV-GPGAVGERTPRKKEPP) of human BRAF-HDAC ... (BHC110/LSD1). Quality Assurance ... Stability 2 years ...
...
Rabbit anti-CUGBP2...
Request Info...
Biology Products: